Artificial intelligence (AI) and machine learning have the potential to accelerate innovations in health care. Deep Genomics, a spinoff company led by University of Toronto researcher Brendan Frey, is helping bring new treatments to market for rare and genetic diseases by leveraging AI and machine learning to accelerate drug discovery.
As an emerging leader in the Canadian biotechnology space, Deep Genomics has secured US$180-million in financing with support from investors and collaborators around the world including Japan and the United States in addition to Canadian investors.
The backing for Deep Genomics is one of the largest financings by a Canadian artificial intelligence company and the second investment in the country’s fast-growing biotechnology space. Deep Genomics currently has 10 drugs in pre-clinical development, four of which are set to enter human trials by mid-2023.
For more information, visit the University of Toronto.
